Brief: Y-mAbs Announces First Patient Dosed In Phase 1 Clinical Trial Of GD2-SADA
05/04/2023 14:36
April 5 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O :
* Y-MABS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL
TRIAL
OF GD2-SADA
* Y-MABS THERAPEUTICS INC - COMPANY EXPECTS A TOTAL OF
APPROXIMATELY 60 PATIENTS TO BE ENROLLED IN GD2-SADA TRIAL
ACROSS 6-10 U.S. SITES
Source text for Eikon: ID:nGNX9Wdw27
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Y-mAbs Therapeutics
See all newsY-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary